Diovan High Blood Pressure Medication Sales Hit Over $6 billion Worldwide

Jan. 25, 2011 - PRLog -- According to the report “Valsartan - Key patent, SPC, and data exclusivity expiry (7 country coverage)” available at http://www.piribo.com/publications/generic_drugs/patent_reports/valsartan_core_country_coverage.html Valsartan, an angiotensin II receptor antagonist, developed by Novartis and marketed as its flagship-product, is sold under the brand name Diovan.  Labelled the “world’s number-one selling high blood pressure medication”, Diovan accounted for US $6 billion in sales worldwide in 2009. With patent protection on its active ingredient due to expire in most major territories in the near future, this month’s Drug In Focus analyses the patent landscape surrounding Valsartan based on information contained in GenericsWeb's Pipeline Selector report.

Novartis has undertaken active measures with its life cycle management of Valsartan by filing patent term extensions, researching and developing fixed-dose combinations and gaining approval for new paediatric indications thus earning extra extensions in key territories. However, with the looming expiry of the 578 US patent and equivalents, generic companies having already shown an aggressive approach with regards to patent filing are provided with a great opportunity to enter the high blood pressure therapies market. Novartis, on the other hand will perhaps aim to secure future revenues by hoping it can convince medical practitioners and patients alike of the benefits of its fixed-dose combination products that expire much later.

The report “Valsartan - Key patent, SPC, and data exclusivity expiry (7 country coverage)” is available from Piribo at:
http://www.piribo.com/publications/generic_drugs/patent_r...
Piribo product ID: GEW00596

About Piribo

Piribo http://www.piribo.com/publications/generic_drugs/patent_r... is the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books. Piribo has ongoing relationships with leading market research and publishing companies, so we can offer you a current and comprehensive range of specialised intelligence.

# # #

About Piribo.
Piribo http:www.piribo.com is the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books.